Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA rejects claims of undue industry influence on data disclosure policy

This article was originally published in Scrip

Executive Summary

The European Medicines Agency has dismissed suggestions that the 2013 appointment of a new head of legal services with an industry background had a significant influence on the development of its draft policy on clinical trial data disclosure. It has also sharply rejected the idea that it does not pay sufficient attention to the interests of patients.

You may also be interested in...



Coronavirus Notebook: Leading Vaccines Near Approval, EU Signs More Advance Purchase Deals

Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.

EU Prepares To Reveal Pharma Strategy

The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.

Brexit: Medtech Firms Told To Act Now To Prevent Supply Problems In January

In its latest communication to medical product companies, the DHSC says the biggest potential cause of disruption to supplies could be failure to prepare for border controls implemented by the EU member states after the end of the Brexit transition period.

Topics

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel